Sheerin K. Shahidi-Latham, Ph.D., is the Vice President of Pre-clinical Development at Nitrase Therapeutics. Dr. Shahidi-Latham brings nearly 20 years of biotech and pharmaceutical experience ranging from early target validation to clinical development. Prior to joining Nitrase Therapeutics, she served as a Senior Director of the ICF Disease Team and Translational Medicine at Bristol Myers Squibb (BMS). During her tenure at BMS, Dr. Shahidi-Latham developed and executed biomarker-based strategies for clinical development programs, while also co-leading a cross-functional translational steering committee charged with defining, prioritizing, and directing the execution of reverse translational efforts. Prior to BMS, Dr. Shahidi-Latham was the Senior Director of Biomarkers and Discovery DMPK at MyoKardia, Inc., a clinical stage biopharmaceutical company utilizing a precision medicine approach to discover, develop, and commercialize targeted therapies for the treatment of rare cardiovascular diseases. Earlier in her career, Dr. Shahidi-Latham served as a Senior Scientist and Head of Metabolomics and Imaging Mass Spectrometry in the Department of Drug Metabolism and Pharmacokinetics at Genentech. Dr. Shahidi-Latham received a Ph.D. in Chemistry from Vanderbilt University under the tutelage of Prof. Richard Caprioli and a B.S. in Biochemistry from Miami University.